Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT01943851
Title A Dose Escalation Study to Investigate the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD) and Clinical Activity of GSK525762 in Subjects With Relapsed, Refractory Hematologic Malignancies
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors GlaxoSmithKline
Indications

refractory hematologic cancer

Therapies

Molibresib

Age Groups: adult
Covered Countries USA | ESP

Facility Status City State Zip Country Details
GSK Investigational Site Little Rock Arkansas 72205 United States Details
GSK Investigational Site Aurora Colorado 80045 United States Details
GSK Investigational Site New York New York 10065 United States Details
GSK Investigational Site Philadelphia Pennsylvania 19104 United States Details
GSK Investigational Site Houston Texas 77030 United States Details
GSK Investigational Site East Melbourne Victoria 3002 Australia Details
GSK Investigational Site Seoul 03722 Korea, Republic of Details
GSK Investigational Site Seoul 06351 Korea, Republic of Details
GSK Investigational Site Barcelona 08036 Spain Details
GSK Investigational Site Madrid 28006 Spain Details
GSK Investigational Site Madrid 28040 Spain Details
GSK Investigational Site Málaga 29010 Spain Details
GSK Investigational Site Salamanca 37007 Spain Details
GSK Investigational Site Cambridge CB2 0QQ United Kingdom Details
GSK Investigational Site London W12 0NN United Kingdom Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field